News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
325–360
Matches
6491
Sources here
17
Companies here
28
Search results Stored financial headlines

Active search

6491 matching headlines

Ticker or company: VERMain company stories
Clear

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

Punch & Associates (IIIV) reports 5.6% beneficial stake in i3 Verticals

Punch & Associates Investment Management, Inc. has reported a beneficial ownership of 1,099,486 shares of i3 Verticals, Inc. common stock, which accounts for 5.6% of the class. The firm holds sole voting and dispositive power over these shares, indicating complete control over the position. …

IIIV main company
Sharemaestro market context Price below Trend Line 52 weeks -48.3% IIIV stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Crinetics Pharmaceuticals (CRNX) advances Vertex merger after key antitrust milestones

Crinetics Pharmaceuticals announced significant progress in its planned acquisition by Vertex Pharmaceuticals, with the Hart-Scott-Rodino waiting period expiring and antitrust approvals secured in Austria, Germany, and Australia. The merger's completion hinges on Crinetics shareholder approval at a meeting on August 28, 2026, with an …

VRTX main company
Sharemaestro market context Trend signal active 52 weeks +28.0% VRTX stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Form 8K Professional Diversity Network Inc For: 14 August By Investing.com

This article reports on the filing of a Form 8K by Professional Diversity Network Inc. on August 14. The filing is a standard regulatory announcement for companies in the stock market. The article provides basic details about the filing and mentions the company's stock …

IPDN main company
Sharemaestro market context Price below Trend Line 52 weeks -87.9% · Next-week setup negative 41.5% IPDN stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Does Clover’s Profit Turn and Raised 2026 Guidance Reshape the Bull Case for CLOV?

Clover Health Investments, Corp. has already reported its second-quarter 2026 results, posting revenue of US$743.17 million versus US$477.62 million a year earlier and moving from a net loss of US$10.58 million to net income of US$28 million. Alongside this shift to profitability, the company …

CLOV main company
Sharemaestro market context Trend signal active 52 weeks +68.5% CLOV stored weekly price path from 22 Aug 2025 to 14 Aug 2026

EverCommerce CEO Eric Remer sells $667,379 of EVCM shares

EverCommerce CEO Eric Remer sold 67,339 shares of EVCM stock for a total of $667,379 between August 11 and August 13, 2026, with prices ranging from $9.8455 to $9.9963 per share. Despite the CEO's sales, InvestingPro analysis indicates that the company is undervalued, with …

EVCM main company
Sharemaestro market context Price below Trend Line 52 weeks -11.7% · Next-week setup positive 62.1% EVCM stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Is Evercore’s (EVR) New Industrials ECM Hire a Clue to Its Evolving Competitive Edge?

Evercore Inc. (EVR) recently hired Dylan Tornay, a senior managing director with extensive equity capital markets experience, to focus on the industrials and infrastructure sectors. This strategic hire aims to bolster Evercore's coverage in these areas and diversify its revenue streams beyond M&A, particularly …

EVR main company
Sharemaestro market context Price below Trend Line 52 weeks -2.9% · Next-week setup positive 60.5% EVR stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Needham cuts Veritone stock price target on revenue pushout concerns

Needham has lowered its price target for Veritone (NASDAQ:VERI) shares from $10.00 to $5.00, while maintaining a Buy rating, due to disappointing Q2 performance and revenue pushout concerns. The company is facing challenges from shifting U.S. Federal priorities away from AI projects and hyperscalers …

VERI main company
Sharemaestro market context Price below Trend Line 52 weeks -51.3% · Next-week setup negative 39.5% VERI stored weekly price path from 22 Aug 2025 to 14 Aug 2026

InvestingPro’s Fair Value spotted UTI’s 46% drop before it happened By Investing.com

InvestingPro's Fair Value models successfully predicted a 46% drop in Universal Technical Institute (NYSE:UTI) stock weeks before it occurred. The analysis flagged UTI as significantly overvalued at $48.24 on July 2, 2026, accurately forecasting a substantial downside risk which materialized as the stock plunged …

UTI main company
Sharemaestro market context Price below Trend Line 52 weeks -6.2% · Next-week setup positive 64.7% UTI stored weekly price path from 22 Aug 2025 to 14 Aug 2026

TD Waterhouse Canada Inc. Cuts Stock Holdings in Verizon Communications Inc. $VZ

TD Waterhouse Canada Inc. reduced its stake in Verizon Communications Inc. by 9.8% in the second quarter, selling 94,416 shares but still holding 867,206 shares valued at $36.4 million. Despite reporting stronger-than-expected quarterly EPS of $1.30, Verizon's revenue fell 0.7% year-over-year, and the company …

VZ main company
Sharemaestro market context Price above Trend Line 52 weeks +14.6% · Next-week setup positive 56.1% VZ stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Kyverna Therapeutics (KYTX): Bain Capital fund reports 4.75% ownership stake

Bain Capital Life Sciences Opportunities III, LP has reported a 4.75% ownership stake in Kyverna Therapeutics, Inc. (KYTX) through a Schedule 13G/A SEC filing. The fund holds 2,885,000 shares of common stock, representing a passive investment based on the company's 60,795,212 outstanding shares as …

KYTX main company
Sharemaestro market context Price below Trend Line 52 weeks +112.2% · Next-week setup negative 41.1% KYTX stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context